Related Experiment Videos
Acute coronary occlusion and in-stent thrombosis in a patient with essential thrombocythemia
T Turgut1, K J Harjai, R Edupuganti
1Department of Cardiology, Ochsner Medical Institutions, New Orleans, Louisiana 70121, USA.
Insights
Essential thrombocythemia, a rare blood disorder, can lead to severe cardiovascular events like heart attacks. This case highlights the complex management of such a patient with extremely high platelet counts.
Area of Science:
- Cardiology
- Hematology
Background:
- Essential thrombocythemia is a myeloproliferative neoplasm characterized by elevated platelet counts.
- High platelet counts increase the risk of thrombotic and hemorrhagic complications.
Observation:
- A 34-year-old male with essential thrombocythemia presented with acute anterior wall myocardial infarction.
- The patient had a markedly elevated platelet count of 2,100,000/mm3.
- Initial treatment involved percutaneous coronary intervention and stenting.
Findings:
- The patient experienced post-procedural stent thrombosis and femoral arterial bleeding, necessitating repeat interventions and surgical repair.
- A comprehensive treatment regimen including platelet pheresis, antiplatelet agents (aspirin, ticlopidine), and cytoreductive therapy (hydroxyurea, anagrelide) was initiated.
Implications:
- This case underscores the critical importance of aggressive management of thrombotic risk in essential thrombocythemia.
- Multidisciplinary approaches are essential for managing complex cardiovascular and bleeding complications in patients with myeloproliferative neoplasms.
- Optimal therapeutic strategies for essential thrombocythemia require balancing antithrombotic and antihemorrhagic needs.
Abstract:
We describe a case of essential thrombocythemia in a 34-year-old male who presented with acute anterior wall myocardial infarction and a platelet count of 2,100,000/mm3. Primary percutaneous coronary angioplasty and stenting were performed. Postangioplasty course was complicated by stent thrombosis requiring repeat coronary angioplasty and persistent femoral arterial bleeding that was treated with surgical exploration and repair. The patient was subsequently treated with platelet pheresis, acetylsalicylic acid, ticlopidine, hydroxyurea, and anagrelide without further complications.